Pilot Study of Lapatinib (Tyverb) in Neoadjuvant Treatment for Patients With Locally Bladder Carcinoma Before Cystectomy.

Trial Profile

Pilot Study of Lapatinib (Tyverb) in Neoadjuvant Treatment for Patients With Locally Bladder Carcinoma Before Cystectomy.

Discontinued
Phase of Trial: Phase 0

Latest Information Update: 10 Jan 2013

At a glance

  • Drugs Lapatinib (Primary)
  • Indications Bladder cancer
  • Focus Biomarker; Pharmacodynamics
  • Acronyms LAPAINBLAD
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Jun 2012 Additional lead trial investigators (Thierry Lebret and Pascal Rischmann) identified as reported by ClinicalTrials.gov.
    • 13 Jun 2012 Planned end date changed from 1 Jan 2012 to 1 May 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top